A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma (Q33579629)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

28 July 2017

phase II clinical trial

0 references

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

object named as

Carmen Ayuso

6

0 references

Alejandro Forner

object named as

Alejandro Forner

2

0 references

object named as

Jordi Bruix

10

0 references

8

object named as

Michael P Manns

1 reference

Europe PubMed Central

28 July 2017

1

object named as

Tim F Greten

1 reference

Europe PubMed Central

28 July 2017

Michel Beaugrand

9

object named as

Michel Beaugrand

1 reference

Europe PubMed Central

28 July 2017

author name string

Firouzeh Korangy

3

1 reference

Europe PubMed Central

28 July 2017

Gisele N'Kontchou

4

1 reference

Europe PubMed Central

28 July 2017

Nathalie Barget

5

1 reference

Europe PubMed Central

28 July 2017

Lars A Ormandy

7

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

17 May 2010

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

10

1 reference

Europe PubMed Central

28 July 2017

209

1 reference

Europe PubMed Central

28 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-10-209

0 references

FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Molecular therapy for the treatment of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Molecular targeted therapies in hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Immunotherapy of HCC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Immunoregulatory T cells in tumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

21 June 2018

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-209

21 January 2018

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-209

21 January 2018

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-209

21 January 2018

MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-209

21 January 2018

T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2882353

31 October 2018

Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC

1 reference

https://pubmed.ncbi.nlm.nih.gov/20478057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20478057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four -Fetoprotein Peptides

1 reference

https://pubmed.ncbi.nlm.nih.gov/20478057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20478057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-10-209

1 reference

Europe PubMed Central

28 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33579629&oldid=2080506485"